PT3292144T - Utilização de cd24 para reduzir os níveis de colesterol de lipoproteína de baixa densidade - Google Patents

Utilização de cd24 para reduzir os níveis de colesterol de lipoproteína de baixa densidade

Info

Publication number
PT3292144T
PT3292144T PT167901289T PT16790128T PT3292144T PT 3292144 T PT3292144 T PT 3292144T PT 167901289 T PT167901289 T PT 167901289T PT 16790128 T PT16790128 T PT 16790128T PT 3292144 T PT3292144 T PT 3292144T
Authority
PT
Portugal
Prior art keywords
density lipoprotein
cholesterol levels
lipoprotein cholesterol
lowering low
lowering
Prior art date
Application number
PT167901289T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Oncoimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncoimmune Inc filed Critical Oncoimmune Inc
Publication of PT3292144T publication Critical patent/PT3292144T/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/323—Arteriosclerosis, Stenosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
PT167901289T 2015-05-07 2016-05-06 Utilização de cd24 para reduzir os níveis de colesterol de lipoproteína de baixa densidade PT3292144T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562158157P 2015-05-07 2015-05-07

Publications (1)

Publication Number Publication Date
PT3292144T true PT3292144T (pt) 2020-11-05

Family

ID=57218627

Family Applications (1)

Application Number Title Priority Date Filing Date
PT167901289T PT3292144T (pt) 2015-05-07 2016-05-06 Utilização de cd24 para reduzir os níveis de colesterol de lipoproteína de baixa densidade

Country Status (18)

Country Link
US (2) US10369197B2 (cg-RX-API-DMAC7.html)
EP (1) EP3292144B1 (cg-RX-API-DMAC7.html)
JP (1) JP6751756B2 (cg-RX-API-DMAC7.html)
KR (1) KR20170141216A (cg-RX-API-DMAC7.html)
CN (1) CN107531772B (cg-RX-API-DMAC7.html)
AU (1) AU2016258084B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017022394A2 (cg-RX-API-DMAC7.html)
CA (1) CA2982612A1 (cg-RX-API-DMAC7.html)
EA (1) EA038520B1 (cg-RX-API-DMAC7.html)
ES (1) ES2829235T3 (cg-RX-API-DMAC7.html)
HK (1) HK1249521A1 (cg-RX-API-DMAC7.html)
HR (1) HRP20201651T1 (cg-RX-API-DMAC7.html)
HU (1) HUE051866T2 (cg-RX-API-DMAC7.html)
IL (1) IL255086B (cg-RX-API-DMAC7.html)
MX (1) MX385941B (cg-RX-API-DMAC7.html)
PT (1) PT3292144T (cg-RX-API-DMAC7.html)
WO (1) WO2016179456A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201706846B (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1249521A1 (zh) * 2015-05-07 2018-11-02 肿瘤免疫股份有限公司 Cd24用於降低低密度脂蛋白胆固醇水平的用途
SG11201908077XA (en) * 2017-03-07 2019-09-27 Oncoimmune Inc Methods of use of soluble cd24 for treating systemic lupus erythematosus
WO2019113123A1 (en) * 2017-12-04 2019-06-13 Precithera, Inc. TGF-ß RECEPTOR FUSION PROTEINS AND OTHER TGF-ß ANTAGONISTS FOR REDUCING TGF-ß SIGNALING
US20210046154A1 (en) * 2018-03-05 2021-02-18 Oncoimmune, Inc Methods of use of soluble cd24 for treating acquired immune deficiency syndrome (hiv/aids)
TW202015753A (zh) * 2018-06-04 2020-05-01 美商昂科免疫公司 以cd24預防及治療移植物抗宿主病及黏膜炎之方法
KR102559149B1 (ko) 2018-10-26 2023-07-24 에프. 호프만-라 로슈 아게 재조합효소 매개 카세트 교환을 이용한 다중특이적 항체 스크리닝 방법
WO2020163529A1 (en) * 2019-02-06 2020-08-13 Oncoimmune, Inc. Targeting cd24-siglec interactions for the treatment and prevention of nonalcoholic steatohepatitis
US20220000974A1 (en) * 2019-02-06 2022-01-06 Oncolmmune, Inc. Targeting CD24-Siglec Interactions for Treating Subjects with Prediabetes or Diabetes
US20230103352A1 (en) * 2020-02-10 2023-04-06 Oncoimmune, Inc. Methods of use of soluble cd24 for treating sars-cov-2 infection
EP4103217A4 (en) * 2020-02-10 2024-03-13 Oncoimmune Inc. METHOD OF USING SOLUBLE CD24 TO TREAT VIRAL PNEUMONIA

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6544566B1 (en) * 1999-04-23 2003-04-08 Protein Technologies International, Inc. Composition containing plant sterol, soy protein and isoflavone for reducing LDL cholesterol
WO2001072325A1 (en) * 2000-03-29 2001-10-04 The Ohio State University Research Foundation Methods of blocking tissue destruction by autoreactive t cells
CN1323544A (zh) * 2000-05-13 2001-11-28 蛋白质技术国际公司 降低低密度脂蛋白胆固醇浓度的组合物和方法
JP2011509244A (ja) * 2007-12-21 2011-03-24 ユニバーシティー オブ ロチェスター 脳の原発性神経腫瘍および神経膠腫における脳腫瘍幹細胞マーカーならびに診断および治療標的としてのcd24
US8163281B2 (en) * 2009-03-04 2012-04-24 The Regents Of The University Of Michigan Treatment of drug-related side effect and tissue damage by targeting the CD24-HMGB1-Siglec10 axis
US8354520B2 (en) * 2009-12-10 2013-01-15 Kaohsiung Medical University Composition and method for treating atherosclerosis, method for determining if a subject has atherosclerosis and method of screening an anti-atherosclerotic drug
US20130231464A1 (en) * 2010-04-28 2013-09-05 Oncolmmune, Inc. Methods of use of soluble cd24 for therapy of rheumatoid arthritis
ES2826445T3 (es) * 2010-04-28 2021-05-18 Oncolmmune Inc Uso médico de CD24 soluble
US20140357505A1 (en) * 2011-06-10 2014-12-04 The Trustees Of The University Of Pennsylvania System And Method Of Cytomic Vascular Health Profiling
HK1249521A1 (zh) * 2015-05-07 2018-11-02 肿瘤免疫股份有限公司 Cd24用於降低低密度脂蛋白胆固醇水平的用途

Also Published As

Publication number Publication date
ES2829235T3 (es) 2021-05-31
JP2018515605A (ja) 2018-06-14
ZA201706846B (en) 2018-12-19
EP3292144A1 (en) 2018-03-14
CN107531772A (zh) 2018-01-02
EP3292144B1 (en) 2020-08-26
WO2016179456A1 (en) 2016-11-10
AU2016258084B2 (en) 2020-01-30
HRP20201651T1 (hr) 2020-12-25
US10369197B2 (en) 2019-08-06
HK1249521A1 (zh) 2018-11-02
AU2016258084A1 (en) 2017-11-02
CN107531772B (zh) 2021-09-21
EA038520B1 (ru) 2021-09-09
EP3292144A4 (en) 2018-11-14
US11026995B2 (en) 2021-06-08
US20190307841A1 (en) 2019-10-10
JP6751756B2 (ja) 2020-09-09
MX385941B (es) 2025-03-18
IL255086A0 (en) 2017-12-31
HUE051866T2 (hu) 2021-03-29
BR112017022394A2 (pt) 2018-07-17
KR20170141216A (ko) 2017-12-22
CA2982612A1 (en) 2016-11-10
MX2017014095A (es) 2018-03-16
IL255086B (en) 2021-08-31
EA201792418A1 (ru) 2018-02-28
US20180110828A1 (en) 2018-04-26

Similar Documents

Publication Publication Date Title
AU2016258084B2 (en) Use of CD24 for lowering low-density lipoprotein cholesterol levels
PT3389404T (pt) Mistura de hmos
EP3123804A4 (en) Mechanisms of virtual clear channel assessment for wi-fi devices
HUE055536T2 (hu) Átvezetés
DK3209673T3 (en) Mixtures of HMOs
IL236245A0 (en) A self-balancing aerial observation device
GB201419214D0 (en) Bearing apparatus
GB201607853D0 (en) Fixing apparatus
IL256980B1 (en) Compounds for inducing tissue formation and their uses
GB2529470B (en) Climbing screen support
GB201414395D0 (en) X-ray apparatus
SG10201609458XA (en) Elevator Apparatus
SG10201501934WA (en) Door of platform door apparatus
GB2537007B (en) Fixing apparatus
GB201611994D0 (en) Medical apparatus
GB2547396B (en) Apparatus for securing two members together
PT3129150T (pt) Moinho de esferas agitador com uma passagem de eixo
GB2541697B (en) Walking support apparatus
TWM490285U (en) Descending stopper of curtain set
IL286670A (en) Compounds for inducing tissue formation and their uses
IL256968A (en) Compounds for inducing tissue formation and uses thereof
EP3116420B8 (en) Apparatus for treatment of patellofemoral conditions
GB201420697D0 (en) Duplex bearings for telescopic structures
GB2527735B (en) Lid interlock apparatus
TWM533161U (en) Improved support structure for monitor